Table 1 Characteristics of patients enrolled in the study

From: A multiparameter liquid biopsy approach allows to track melanoma dynamics and identify early treatment resistance

Patient ID

Sex

Age

Mutationa

Disease sites

Stage IV subcategory

Best response (RECIST)

EP

Progression sites

Survival status

Number of samples

1

F

75

p.V600E

Brain, lymph nodes, lung

M1d

PR

N

Brain

Dead

3

3

F

81

p.V600K

Liver

M1c

SD

N

Liver

Dead

3

6

F

42

p.V600E

Peritoneum

M1c

PR

N

Peritoneum

Dead

4

8

M

85

p.V600E

Brain, liver, lymph nodes, lung

M1d

PR

N

Brain, lung, soft tissues, lymph nodes

Dead

3

9

F

37

p.V600E

Soft tissue, lymph nodes, liver, adrenal gland, bones, peritoneum

M1c

PR

N

Soft tissues, liver, heart

Dead

4

10

F

65

p.V600Kb

Brain, lymph nodes, lung, liver

M1d

PR

N

Brain

Dead

4

12

M

59

p.V600E

Lymph nodes

M1a

CR (SR)

N

NA

Alive

3

13

F

42

p.V600E

Brain, peritoneum, lymph nodes, liver, soft tissues, lung, adrenal gland

M1d

PR

Y

Brain

Dead

4c

15

F

46

p.V600Eb

Lung, bones

M1c

PR (SR)

N

NA

Alive

3

17

M

48

p.V600E

Soft tissues, thoracic wall, bones, subcutaneous, abdominal wall

M1c

CR

Y

Bones, soft tissues, peritoneum, lung

Dead

2

19

M

64

p.V600E

Lung, lymph nodes

M1b

PD

Y

Brain, lung, spleen, lymph nodes

Dead

2

24

M

51

p.V600Eb

Tonsils, lymph nodes

M1c

CR (SR)

N

NA

Alive

3

27

M

85

p.V600K

Lymph nodes, liver

M1c

PR

N

Liver, lung, adrenal gland, spleen

Dead

4

28

M

84

p.V600E

Subcutaneous, lymph nodes, liver, bones

M1c

PR

N

Adrenal gland, brain

Dead

3

34

F

75

p.V600Kb

Lung

M1b

PD

Y

Peritoneum, lung

Dead

1

48

M

59

p.T599dup

Pleura, lung, lymph nodes

M1b

PR

N

Pleura, liver, lymph nodes, brain

Alive

3

49

M

64

p.V600E

Brain, liver, lung, lymph nodes, bones

M1d

PD

Y

Brain

Dead

1

  1. SD stable disease, PR partial response, CR complete response, SR still responding, PD progressive disease, EP early progression, i.e. progression free survival ≤6 months, Y yes, N no, NA not appropriate, Number of samples total number of plasma samples collected for every patient.
  2. aBRAF mutation identified in the liquid biopsy if not otherwise indicated.
  3. bBRAF mutation identified in the FFPE tissue sample.
  4. cAdditional samples corresponding to therapy change after progression and one month later were analyzed46.